

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number  
WO 01/74389 A2

(51) International Patent Classification<sup>7</sup>: A61K 41/00

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(21) International Application Number: PCT/EP01/03265

(22) International Filing Date: 22 March 2001 (22.03.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
60/191,807 24 March 2000 (24.03.2000) US

Published:

— without international search report and to be republished upon receipt of that report

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BRAZZELL, Romulus, Kimbro [US/US]; 9705 Foxworth Drive, Alpharetta, GA 30201 (US).



WO 01/74389 A2

(54) Title: IMPROVED TREATMENT OF NEOVASCULARIZATION

(57) Abstract: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).

## IMPROVED TREATMENT OF NEOVASCULARIZATION

The invention relates to an improved method to treat subfoveal choroidal neovascularization (CNV) by use of an anti-angiogenic agent as an adjunct to photodynamic therapy (PDT) also 5 called photodynamic treatment.

The present treatment of age related macular degeneration (AMD) with photodynamic therapy using an appropriate photosensitizer leads to excellent short-term results for treating CNV and is a significant improvement over laser photocoagulation. However, it has been demonstrated 10 that in patients treated with PDT there is a recurrence of choroidal neovascularization within the treatment area and/or development of new lesions outside the original lesions (so called progression) such that repeated PDT is required. Therefore a pharmaceutical treatment which could be used in conjunction with PDT, and which prevents the growth of new vessels would be a significant advancement and would be advantageous for the treatment of CNV. The 15 prevention of new unwanted neovasculation could reduce the number of PDT treatments required in some subjects. The present techniques may also be useful for treating other types of ocular tissue as well, such as retinal neovascular lesions.

Accordingly, the present invention describes in a first aspect a method for an improved 20 treatment of unwanted neovasculation due to CNV in a subject, which method comprises:  
(a) administration of an effective amount of an anti-angiogenic drug to said subject;  
(b) administration of an effective amount of a photosensitive agent to said subject; and  
(c) irradiating said unwanted neovasculation with light having a wavelength absorbable said 25 photosensitive agent.

The present invention relates in a further aspect to the use of an anti-angiogenic drug in conjunction with a photosensitive agent in the preparation of a medicament for the improved photodynamic treatment of unwanted neovasculation due to CNV in a subject, preferably a human subject.

30 The invention relates in a further aspect to the use of an anti-angiogenic drug in conjunction with a photosensitive agent in the preparation of a medicament for the improved photodynamic

treatment of unwanted neovasculature due to CNV in a subject, preferably human subject, wherein said improved photodynamic treatment comprises the steps of:

(a) administration of an effective amount of an anti-angiogenic drug to said subject;

(b) administration of an effective amount of a photosensitive agent to said subject; and

5 (c) irradiating said unwanted neovasculature with light having a wavelength absorbable said photosensitive agent.

It has now been found that administration of an anti-angiogenic can be used in conjunction with PDT for the treatment of a subject having unwanted ocular neovasculature as a result of

10 CNV.

PDT as a treatment is well known in the art, and generally involves the use of a photosensitizing agent activated by a laser. A preferred PDT treatment having a photosensitizing agent and laser treatment protocol is disclosed in the issued European patent EP 680'365 B1 and in the  
15 International application WO 97/33619. In PDT, the photosensitive agent lodges in the ocular tissue affected by CNV (i.e., the target ocular tissue) and is activated by a laser having a wavelength absorbable by the photosensitive agent. In the present invention, the anti-angiogenic drug is administered before, after and / or simultaneously with the photosensitizer used in the PDT treatment. The combination of PDT and anti-angiogenic drug is referred to as  
20 adjunctive PDT.

The anti-angiogenic may be administered either sequentially or simultaneously with the photosensitive agent, the preferred method being sequential. Therefore, the term "in conjunction with" shall be construed in accordance to the definitions as provided within this disclosure. As an example of sequential treatment, an anti-angiogenic drug may be administered for 1 to 4 weeks, more preferably 0.5 to 1.5 weeks before administration of the PDT photosensitizer. In an alternative sequential treatment, the anti-angiogenic may be administered 0 to 4 weeks, more preferably 0 to 1 weeks after administration of the PDT photosensitizing agent. If necessary, the anti-angiogenic may be sequentially administered both before and after PDT according to the schedule described above. Alternatively, the treatment is considered simultaneous if the anti-angiogenic is co-administered with the photosensitizer. Particular subjects may require multiple adjunctive PDT treatments or adjunctive PDT


treatments with the anti-angiogenic and particular adjunctive PDT treatments may require multiple administrations of the anti-angiogenic drug.

**Anti-angiogenic drugs, as the term is used herein mean drugs that work by preventing,**


5 inhibiting or reversing the growth of new blood vessels via the process commonly known as angiogenesis. Examples of anti-angiogenic drugs useful in adjunctive PDT include staurosporins, for example N-benzoyl-staurosporine, somatostatins, such as octreotide

(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys-Thr-ol, and steroids, such as triamcinolone. Other anti-angiogenic drugs useful in the present invention are VEGF inhibitors, such as CGP 79987D,


10 CGP 57 148B or CGP 53 716,



CGP 79787D



CGP 53716



CGP 57'148

15

and the like. These anti-angiogenic drugs are particularly useful to inhibit the recurrence, re-opening, development and / or progression of blood vessel growth that occurs during choroidal neovascularization, and offer significant benefits in adjunctive PDT.

A preferred anti-angiogenic drug is selected from inhibitors of protein kinase C (PKC) (e.g., N-benzoyl-staurosporine), inhibitors of growth hormone and IGF-1 (e.g., octreotide), inhibitors of vascular endothelial growth factor (VEGF) (e.g., CGP 79787, N-benzoyl-staurosporine, CAM 5 781), inhibitors of cyclooxygenase II (e.g., diclofenac, COX 189), inhibitors of angiotensin II (e.g., valsartan), inhibitors of NF-kappa B, and PLA2 antagonists, more preferably from PKC inhibitors, VEGF inhibitors and from inhibitors of growth hormone and IGF-1.

A highly preferred anti-angiogenic drug is selected from an inhibitor of PKC and VEGF, in 10 particular from an inhibitor of PKC. A highly preferred anti-angiogenic drug is selected from N-benzoyl-staurosporine, CGP 79787 and octreotide and in particular from N-benzoyl-staurosporine.

The preferred photosensitizers are selected from the group of a chlorine, a bacteriochlorine, a 15 phthalocyanine, a porphyrin, a purpurin, a merocyanine, a pheophorbide and a psoralen.

A highly preferred photosensitizer is selected from the porphyrins and is typically the so-called green porphyrin or BPD-MA.

20 Any of the photosensitive compounds described above can be used in the method of the invention. Of course, mixtures of two or more photosensitive compounds can also be used; however, the effectiveness of the treatment depends on the absorption of light by the photosensitive compound so that if mixtures are used, components with similar absorption maxima are preferred.

25 The nature of the formulation used to deliver the anti-angiogenic drug or photosensitive agent will depend in part on the mode of administration and on the nature of the anti-angiogenic drug and the photoactive agent selected. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to the particular active compounds may be used. Thus, the 30 photosensitive agents or anti-angiogenic compounds may be administered as an aqueous composition, as a transmucosal or transdermal composition, as a subtenons or intraocular injection or in an oral formulation. The formulation may also include liposomes. Liposomal

compositions are particularly preferred especially where the photoactive agent is a green porphyrin. The anti-angiogenic drug is preferably administered via an aqueous carrier.

The above mentioned compounds can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally, or the compound may be placed directly in or on the eye. Parenteral administration, such as intravenous, intramuscular, or subcutaneous, is preferred for the photosensitizer. Intravenous injection is especially preferred. Oral administration or ocular administration is preferred for administration of the anti-angiogenic agent.

10

The dose of the above compounds can vary widely depending upon the mode of administration; the formulation in which it is carried, such as in the form of liposomes, or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment. As is generally recognised, there is a nexus between the type of photoactive agent, the formulation, the mode of administration, and the dosage level. The anti-angiogenic drug is administered in a manner and amount sufficient to effect drug interaction with the unwanted neovasculature. The photosensitive agent is administered in an amount effective to provide closure to the unwanted neovasculature.

20

While various photoactive compounds require different dosage ranges, if green porphyrins are used, a typical dosage is of the range of 0.1-50 mg/m<sup>2</sup> of body surface area, preferably from about 1-10 mg/m<sup>2</sup> and even more preferably about 2-8 mg/m<sup>2</sup>.

25

While various anti-angiogenic compounds require different dosage ranges, a typical dosage is of the range of 1-500 mg/kg (of body weight) preferably from about 10-250 mg.

The irradiation (laser power, irradiation duration) is carried out in accordance to the prior art mentioned above, for example in accordance to the light treatment protocol of the disclosure of WO 97/33619.

30

## CLAIMS:

1. Use of an anti-angiogenic drug in conjunction with a photosensitive agent in the preparation of a medicament for the improved photodynamic treatment of unwanted neovasculature due to CNV in a subject.  
5
2. Use of claim 1, wherein said improved photodynamic treatment comprises the steps of:
  - (a) administration of an effective amount of an anti-angiogenic drug to said subject;
  - (b) administration of an effective amount of a photosensitive agent to said subject; and
  - 10 (c) irradiating said unwanted neovasculature with light having a wavelength absorbable said photosensitive agent.
3. Use of claim 1-2, wherein said anti-angiogenic drug is administered 1 to 4 weeks before the administration of said photosensitive agent.  
15
4. Use of claim 1-2, wherein the administration of said anti-angiogenic drug and said photosensitize agent is carried out simultaneously.
5. Use of claim 1-2, wherein the administration of the anti-angiogenic drug is carried out for  
20 1 to 4 weeks after the administration of said photosensitize agent.
6. Use of claim 1, wherein said anti-angiogenic drug is selected from inhibitors of protein kinase C, inhibitors of growth hormone and IGF-1 inhibitors of vascular endothelial growth factor, inhibitors of cyclooxygenase II, inhibitors of angiotensin II, inhibitors of NF-kappa B, and  
25 PLA2 antagonists.
7. Use of claim 6, wherein said anti-angiogenic drug is selected from inhibitors of PKC and VEGF, in particular from an Inhibitor of PKC.
- 30 8. Use of claim 7, wherein said anti-angiogenic drug is selected from N-benzoyl-staurosporine, CGP 79787 and octreotide and in particular from N-benzoyl-staurosporine.

9. Use of claim 1, wherein said photosensitizer agent is selected from a porphyrin and a purpurin and more preferably from a porphyrin.

10. A method for an improved treatment of unwanted neovasculature due to CNV in a  
5 subject, which method comprises;

- (a) administration of an effective amount of an anti-angiogenic drug to said subject;
- (b) administration of an effective amount of a photosensitive agent to said subject; and
- (c) irradiating said unwanted neovasculature with light having a wavelength absorbable by said photosensitive agent.

10

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number  
WO 01/074389 A3

(51) International Patent Classification<sup>7</sup>: A61K 41/00, A61P 27/02

(21) International Application Number: PCT/EP01/03265

(22) International Filing Date: 22 March 2001 (22.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/191,807 24 March 2000 (24.03.2000) US

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BRAZZELL, Romulus, Kimbro [US/US]; 9705 Foxworth Drive, Alpharetta, GA 30201 (US).

(74) Agent: BECKER, Konrad: Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
11 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/074389 A3

(54) Title: IMPROVED TREATMENT OF NEOVASCULARIZATION

(57) Abstract: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).

**INTERNATIONAL SEARCH REPORT**

In' stational Application No  
PCT/EP 01/03265

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K41/00 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBASE, BIOSIS, CHEM ABS Data, EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 33619 A (QLT PHOTOTHERAPEUTICS INC) 18 September 1997 (1997-09-18) cited in the application claims ---	1-10
Y	CIULLA T A ET AL: "CHANGING THERAPEUTIC PARADIGMS FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION: ANTIANGIOGENIC AGENTS AND PHOTODYNAMIC THERAPY" EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 8, no. 12, 1999, pages 2173-2182, XP000978671 ISSN: 1354-3784 page 2178, column 1, paragraph 3 ---	1-10
X	---	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*V\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*g\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 April 2002

10/05/2002

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

## INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/03265

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 00 37107 A (MASFERRER JAIME L ;GORDON GARY (US); SEARLE & CO (US); KOKI ALANE) 29 June 2000 (2000-06-29) claims; example 5 ---	1-10
P,X	FERRARIO A. ET AL.: "Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma" CANCER RESEARCH, vol. 60, no. 15, August 2000 (2000-08), pages 4066-4069, XP002196252 MD US page 4066, column 2, line 36 - line 38 abstract ---	1
E	WO 01 58240 A (MASSACHUSETTS EYE AND EAR IN R) 16 August 2001 (2001-08-16) claims 1,6,7 ---	1-10
E	WO 01 51087 A (LIGHT SCIENCES CORP ;CHEN JAMES (US)) 19 July 2001 (2001-07-19) claims -----	1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-10 relate to an extremely large number of possible compounds. In fact, the claims contain so many options that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely compounds recited in the claims and closely related homologous compounds

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/03265

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9733619	A 18-09-1997	US 5756541 A		26-05-1998
		AU 705100 B2		13-05-1999
		AU 1762697 A		01-10-1997
		CA 2248087 A1		18-09-1997
		WO 9733619 A1		18-09-1997
		CN 1213314 A		07-04-1999
		CZ 9802789 A3		12-05-1999
		EP 0894009 A1		03-02-1999
		FI 981954 A		10-11-1998
		JP 2000506173 T		23-05-2000
		NO 984163 A		11-11-1998
		PL 328796 A1		15-02-1999
		TW 448045 B		01-08-2001
		US 5910510 A		08-06-1999
		ZA 9701820 A		10-10-1997
WO 0037107	A 29-06-2000	AU 2207000 A		31-07-2000
		AU 2209800 A		31-07-2000
		AU 2210400 A		31-07-2000
		AU 2380500 A		31-07-2000
		AU 2592600 A		31-07-2000
		AU 2593600 A		12-07-2000
		AU 2713400 A		31-07-2000
		AU 2713500 A		31-07-2000
		AU 2713600 A		31-07-2000
		BR 9916518 A		29-01-2002
		BR 9916536 A		02-01-2002
		BR 9916544 A		08-01-2002
		EP 1140177 A2		10-10-2001
		EP 1140178 A2		10-10-2001
		EP 1140179 A2		10-10-2001
		EP 1140192 A2		10-10-2001
		EP 1140193 A2		10-10-2001
		EP 1140194 A2		10-10-2001
		EP 1140181 A1		10-10-2001
		EP 1140182 A2		10-10-2001
		EP 1140183 A1		10-10-2001
		NO 20013064 A		23-08-2001
		NO 20013155 A		22-08-2001
		NO 20013156 A		23-08-2001
		WO 0038715 A2		06-07-2000
		WO 0038716 A1		06-07-2000
		WO 0038665 A2		06-07-2000
		WO 0038717 A2		06-07-2000
		WO 0038786 A2		06-07-2000
		WO 0038730 A2		06-07-2000
		WO 0038718 A2		06-07-2000
		WO 0038719 A1		06-07-2000
		WO 0037107 A2		29-06-2000
WO 0158240	A 16-08-2001	AU 3497901 A		20-08-2001
		WO 0158240 A2		16-08-2001
WO 0151087	A 19-07-2001	AU 2783701 A		24-07-2001
		WO 0151087 A2		19-07-2001

**THIS PAGE BLANK (USPTO)**